Dividend Powerhouses with yields above 5% can offer a way to keep income flowing even while inflation, interest rates and growth signals move in different directions across regions. With central banks watching prices closely and manufacturing and retail data sending mixed messages, many investors are looking for companies that provide regular cash returns that are well covered, growing and stable. This Dividend Powerhouses screener focuses on exactly that. In this article, you will see three stocks from the screener that could help anchor an income focused portfolio with reliable dividend streams.

AngloGold Ashanti (AU)

Overview: AngloGold Ashanti is a global gold producer that operates mines across Africa, Australia and the Americas, with its flagship Geita mine in Tanzania and additional by-products such as silver and sulphuric acid. The company focuses on discovering, mining and processing gold, then selling it into international markets.

Operations: AngloGold Ashanti generates about US$11.8b in revenue predominantly from metals and mining activities in gold and other precious metals, with most revenue coming from Africa at US$8.5b, followed by Australia at US$2.4b and the Americas at US$2.3b.

Market Cap: US$41.7b

Income investors may find AngloGold Ashanti interesting because it combines a sizeable gold production base with profitability and shareholder returns, including a Q2 2026 interim dividend of US$364m and an approved share buyback program of up to US$2.0b. The company has reported high margins, and recent cash flow has supported both investment in projects such as North Bullfrog and Arthur and ongoing dividends. The main watchpoints are rising costs, an uneven dividend record and reliance on supportive gold prices. For investors who want a high margin gold producer with active capital returns in a Dividend Powerhouses context, there is more to unpack in the detail of its valuation, growth profile and risk balance.

AngloGold Ashanti’s high margins, cash backed dividends and buybacks could be masking a more complex story about what really underpins those shareholder returns. Get the full picture in the 4 key rewards and 1 important warning sign

Accenture (ACN)

Overview: Accenture is a global consulting and technology services company that helps large businesses and public sector clients design, build and run their operations, from cloud and AI projects through to outsourcing, cybersecurity and managed services. It works across industries such as financial services, healthcare, consumer goods and energy, often acting as a long term partner across multiple functions.

Operations: Accenture generates most of its revenue from its Products segment at about US$22.3b, followed by Health & Public Service at about US$14.9b, Financial Services at about US$13.8b, Communications, Media & Technology at about US$12.4b and Resources at about US$9.8b.

Market Cap: US$101.4b

Income focused investors may want to pay attention to Accenture because it blends a roughly 3.8% dividend yield with a return on equity of 23.7% and a P/E multiple below both the wider US market and the IT industry. The company has recently won complex contracts such as multi year NATO cloud and security work and has been building partnerships around agentic AI with Google Cloud and ServiceNow. On the other hand, the business has been experiencing slower revenue and earnings growth than the broader US market, some recent margin pressure, and the need to manage funding risk and a large workforce through an AI driven shift in how technology services are delivered. These factors raise questions about how durable current profitability and capital returns may be.

Accenture’s mix of a roughly 3.8% yield, strong 23.7% return on equity and a P/E below peers suggests something important is being missed. See how the analysis report for Accenture could reframe both the opportunity and the risk.

Medtronic (MDT)

Overview: Medtronic is a large medical technology company that makes devices such as heart pacemakers and defibrillators, spinal and brain implants, surgical tools, and diabetes management systems, which hospitals and doctors use to diagnose, monitor, and treat chronic conditions around the world.

Operations: Medtronic generates most of its revenue from its Cardiovascular portfolio at about US$14.0b, followed by Neuroscience at about US$10.3b, Medical Surgical at about US$8.8b and Other at about US$3.2b, with sales split fairly evenly between the United States at about US$18.1b and the rest of the world at about US$18.1b.

Market Cap: US$111.0b

Income investors may be drawn to Medtronic because it couples a 3.29% dividend yield and 49 years of consecutive increases with exposure to long term demand for treating chronic diseases, supported by acquisitions in areas like AI based coronary assessment and pain therapy. At the same time, earnings growth has been modest, margins have come under some pressure, and parts of the portfolio, including US Diabetes and some Surgical and Neuroscience lines, have been lagging. With the Diabetes spin off, ongoing product recalls, and heavy R&D and commercial spend, there is a question about whether the current valuation and analyst optimism fully reflect the execution and funding risks associated with those steady dividends.

Medtronic’s 49 year dividend run and steady 3.29% yield hint at a story that goes beyond recent margin pressure. See how the analyst forecasts for Medtronic could reshape how you think about the Diabetes spin off and those recalls.

The three dividend stocks covered here are just a starting point, since the full screen has surfaced 81 more companies with 5%+ yields and equally compelling income narratives inside the Dividend Powerhouses (3%+ Yield) screener. Use Simply Wall St to identify and analyze the specific catalysts, dividend histories and risk factors that matter most to you, so you can focus on the highest conviction ideas for a long term income portfolio.

Take Control of Your Investment Journey

If Medtronic or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Stock Ideas Now?

Some of the most interesting opportunities start to break out quietly while few are watching. Use these fresh screens before the momentum is widely caught and act now.

• Spot cash rich businesses with room to move by scanning a curated list of solid balance sheet and fundamentals (49 results). This keeps financial strength front and center while it still flies under the radar for now.
• Hunt for powerful long term themes by checking a hand picked 19 top founder-led companies. Here leadership is deeply invested in every decision and market reaction can shift quickly.
• Zero in on dependable cash generators using a tightly filtered 82 resilient stocks with low risk scores so you focus on resilience while it matters and before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.